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Abstract
We intend to analyse retrospectively whether the time interval (‘‘gap duration’’/GD) between preoperative radiotherapy
and surgery in locally advanced rectal cancer (LARC) has an impact on overall survival (OS), cancer specific survival (CSS),
disease free survival (DFS) and local control (LC). Two hundred seventy nine patients with LARC were entered in Trial
93-01 (hyperfractionated accelerated radiotherapy 41.6 Gy/26 Fx BID) shortly followed by surgery. From these 250
patients are fully assessable. The median GD of 5 days was used as a discriminator. The median follow-up for all patients
was 39 months. GD/5 days was a significant discriminator for actuarial 5-years OS (69% vs 47%, p/0.002), CSS (82% vs
57%, p/0.0007), DFS (62% vs 41%, p/0.0003) but not for LC (93% vs 90%, p/non-significant). In multivariate
analysis, the following factors independently predict outcome; for OS: age, GD, circumferential margin (CM) and nodal
stage (ypN); for CSS: GD, ypN and vascular invasion (VI); for DFS: CEA, distance to anal verge, GD, ypN and VI; for LC:
CM only. Gap duration predicts survival outcome but not local control. The patients submitted to surgery after a median
delay of more than 5 days had a significantly better outcome.
Surgery is the mainstay of treatment in rectal cancer
[19]. The incidence of local recurrence should be
well below 15% provided surgery is performed
according to the now well accepted surgical stan-
dard, which is a total (TME) or a partial mesorectal
excision with sharp dissection. Nevertheless, preo-
perative radiotherapy yields a significant better local
control and in some trials a positive impact on
survival [1015]. In the randomized trials, in which
a clear benefit in favour of 5 times 5 Gy has been
reported, the interval between the end of radio-
therapy and surgery is very short. In the Swedish
rectal cancer trial (SRCT) the patients are submitted
to surgery immediately after the weekend [15]. In
the Dutch ColoRectal Cancer Group trial
(DCRCG), the overall treatment time between the
start of the radiotherapy and the surgery has to be
within 10 days [13]. Therefore, in these trials the
analysis of the impact of the timing of surgery after
the end of radiotherapy is difficult to perform.
In Trial 93-01, a prospective non-randomized
phase II trial on hyperfractionated accelerated radio-
therapy (HART) in locally advanced resectable
rectal cancer (LARC), there is a variation of the
GD. Therefore, we are able to analyze the impor-
tance of the GD on patient’s outcome.
Patients and methods
Trial 93-01 has been designed as a phase II trial to
evaluate the efficacy of HART to increase the local
control rate LARC. The feasibility of hyperfractio-
nation and acceleration has been tested initially in a
postoperative setting (Trial 89-01) [16]. In this time
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period, patients with non-readily resectable rectal
cancer have been submitted to a preoperative
hyperfractionated accelerated schedule of 32 Gy.
Eleven of 12 patients treated with this preoperative
schedule underwent a curative resection (Trial
89-02; unpublished data). Subsequently, we started
a new phase I study (Trial 92-01) increasing the
preoperative total radiation dose to 41.6 Gy in
LARC deemed to be resectable (preoperative
HART followed by surgery after a short interval)
[17].
Trial 93-01, conceived as a phase II trial, has been
extended to a large prospective non-randomized
study in order to have an accurate assessment of
the impact of HARTon the outcome of patients with
LARC (i.e. survival and local control) [18]. This
decision has been submitted and accepted by the
Committee on Human Experimentation of the
participating institutions. This is in agreement with
the Helsinki declaration of 1975.
Patient selection
After oral informed consent, patients were submitted
to a complete clinical examination and laboratory
studies including blood count, biological assessment
of renal and hepatic function and CEA-level. This
was completed with chest X-ray, abdominal ultra-
sound, abdomino-pelvic computed tomography
(CT) and a complete colonoscopy. The local extent
of the tumor was assessed by digital rectal examina-
tion (DRE), transrectal ultrasound (TRUS) and
pelvic CT-scan. The clinical T-stage (cT) was
defined by TRUS and CT. All patients suffering
from histologically confirmed rectal cancer staged
cT3/T4 and any N stage or cN/ and any cT-stage
were eligible for Trial 93-01.
Treatment characteristics
All patients were treated with preoperative HART.
Radiotherapy was performed with a linear accelera-
tor with a minimal accelerating potential of 6 MV
with patients simulated and treated in prone posi-
tion. A total dose of 41.6 Gy was applied in 26
fractions on 17 consecutive days (2 fractions a day
with an interfraction interval of at least 6 hours).
The dose per fraction was 1.6 Gy. No irradiation was
performed over the weekends. The dose prescription
was done at the intersection of the four fields (box-
technique). The requirement of dose homogeneity
were a planning target volume (PTV) covered at
least by the 95% isodose (lower limit) with an upper
limit set at 110%. The four fields were treated twice
a day.
The rectal tumor and the mesorectal space were
considered as part of the clinical target volume
(CTV). The upper limit is set at the L5-S1 inter-
space in order to cover completely the anterior sacral
surface [1921]. The lower limit is defined as a
function of the distance between the lower edge of
the tumor and the anal verge. If the tumor is located
at a distance of 5/5 cm from the anal verge, this
latter is included in the treatment portal as part of
the target volume. The lateral limits of the antero-
posterior (AP) and postero-anterior (PA) fields are
set at 1.5 cm from the internal pelvic bony rim. The
AP-PA fields are completed with two lateral fields
with the same upper and lower limits. The posterior
limit of the lateral field are set behind the sacrum,
whereas the anterior limit is located 3 cm anteriorly
to the most anterior extension of the tumor as
defined on CT. Individualized blocks are designed
to exclude small bowel as much as possible from the
radiation portals [22]. Inclusion of the external iliac
nodes within the clinical target volume (CTV) - in
contrast to internal iliac nodes - is not a protocol
requirement.
The surgery is performed within one week after
completion of the external irradiation. The surgical
technique is decided by the individual surgeons.
However, a TME with sharp dissection is strongly
recommended for tumors in the lower half of the
rectum. For tumors in the upper half a partial
mesorectal excision is suggested [1,2,5]. When a
sphincter sparing surgery is planned, we suggest the
placement of a temporary diverting colostomy to
protect the anastomosis. No radiation therapy is
applied after surgery. No specific guidelines are
defined in Trial 93-01 concerning adjuvant che-
motherapy.
Follow-up
The follow-up of the patients in Trial 93-01 consists
of patient history and physical examination. This is
completed by CEA and TRUS after LAR. If patients
are submitted to APR, TRUS is replaced by CT.
This is performed every three months the first year
and every six months thereafter. If the patients do
not present at their bi-annual exam, the patients are
contacted by phone or information is recovered
through the general practitioner. Every single failure
is recorded and verified by reviewing the multi-
disciplinary patient’s record. Median follow-up is
39 months overall and for surviving patients
52 months.



































Gap duration is used to discriminate between strata.
The median value of 5 days is selected as the cut-off
value (a priori hypothesis). Contingency analysis is
performed for a series of tumor- and patient-related
factors used as categorical data by GD (two-tailed
Fisher’s Exact test is used to test whether a sig-
nificant difference can be observed p5/0.05). To-
gether with other patient- and tumor-related factors,
we tested the predictive power of these variables
using the product limit (Kaplan-Meier) method.
Observed differences in survival curves between the
predefined strata are tested with the log-rank test. A
difference is considered significant provided a p-
value of 5/0.05 is reached. Only factors reaching a
significance level (p5/0.05 log-rank) in the univari-
ate analysis, are introduced in the Proportional
Hazards model (Cox multivariate analysis), to assess
whether they act as independent predictors of out-
come.
Overall survival (OS) is calculated from initiation
of HART until death, whatever the reason of death.
Cancer specific survival (CSS) is calculated con-
sidering local recurrence, distant metastasis or death
due to cancer as an event. Therefore, patients dying
from unrelated causes are not added to the treatment
failures. Events for disease free survival (DFS) are
recurrent disease (local and/or distant), or death of
any cause. Any clinically or radiologically detectable
tumor, whether confirmed by biopsy or not, within
the irradiated volume is labelled a local recurrence.
We are aware that this definition does not allow the
difference between an anostomotic failure, a nodal
failure or a recurrence within the resection bed to be
made. Every abdominal recurrence located outside
of the irradiated pelvis or extra-abdominal failure, is
labelled as a distant failure (metastastic disease).
All calculations are performed on a MacIntosh
Powerbook G4 with JMP 5.0 software (SAS Institute
Inc., Cary, NC, USA).
Results
Two hundred and seventy nine patients with LARC
are enrolled in Trial 93-01 from 1993 to 2002. We
report on 250 assessable patients. Twenty nine
patients are excluded as these patients present with
distant metastases at surgery (n/24) or because of
missing data (n/5). For those patients with hepatic
metastases at surgery, we consider that we could not
label the treatment as curative and those patients are
not considered eligible.
Age ranges from 26 to 85, with a median of 64.
There are 164 male and 86 female patients. The
CEA level ranges fom 0.1 to 713 ng/ml (normal
value (B/5 ng/ml). The median distance to the anal
verge is 5 cm, measured by rigid rectosigmoidoscopy
(mean 5.6 cm, range: 015 cm).
In this cohort of 250 patients, the clinical stage
distribution is as follows: 4 cT2 (but with radiolo-
gical suspicion of nodal involvement on CT), 201
cT3 and 45 cT4. At DRE the tumors are found
clinically tethered or fixed in 78.4% of the cases. As
neither TRUS nor CT could - at that time-provide
sufficiently reliable information on clinical N-stage
(cN), this variable is not analyzed [23,24].
All patients received HART according to the
protocol. There are no reports of treatment inter-
ruption due to acute toxicity. The median gap
duration is 5 days (range 1120 days). The 75th
percentile is 7 days and the 90th percentile is
12 days.
On the 250 patients included, a majority are
submitted to a sphincter sparing procedure (SSP)
(141 patients/56.4%). The pathological stage dis-
tribution after radiotherapy (ypT) is as follows: 3
ypT0 (1.2%), 8 ypT1 (3.2%), 57 ypT2 (22.8%),
161 ypT3 (64.4%) and 21 ypT4 (8.4%). Down-
staging is observed in 38% of the cases. The median
value for the clearance (defined as the distance
between the radial resection margin and the deepest
tumoral infiltration) is 3 mm (range 035 mm). In
118 patients nodes are found positive (47.2%),
whereas in 57 patients (22.8%) vascular invasion
(VI) is reported by the pathologist. In 206 patients
(82.4%), the resection margins are considered mi-
croscopically negative. In the remaining 44 patients
it is essentially the lateral resection margin which is
involved (41/44).
The median follow-up duration is 39 months
overall and 52 months for surviving patients. The
actuarial 5 year results are as follows: for OS 59.69/
3.7% (median not reached); for CSS 71.59/3.5%
(median not reached); for DFS 53.39/3.6% (med-
ian: 79 months). Only 16 patients presented a local
recurrence (crude incidence 6.4%). The actuarial
5-years local control rate is 91.7% (s.e.9/2.2%).
See Figure 1.
The contingency analysis results are summarized
in Table I. No significant association can be high-
lighted between any of the tested tumor- and
patient-related factors and gap duration except for
histopathological tumor differentiation. The tumor
differentiation, however, used to define two strata,
does not yield a significant difference in OS, CSS,
DFS and LC.
The results of the univariate analysis are summar-
ized in Table II. Only factors reaching a statistically
significant p-value of 5/0.05 (log-rank) are listed.
Patients with a longer GD (/5 days) have a better
OS, DFS and CSS (the quantitative data for each


































endpoint and for the two strata are reported in Table
III). As there are no significant differences between
the groups determined by GD in local recurrence
rates at 5 years, the observed difference in DFS is
mainly due to a difference in distant metastases.
For the multivariate analysis, factors reaching a
p-value of 5/0.05 (log-rank) in the univariate
analysis are introduced in the proportional hazards
model. The final model for OS, CSS, DFS and LC is
tabulated with corresponding risk ratios and con-
fidence limits (Table IV).
Discussion and conclusion
The actuarial local control rate in Trial 93-01 is
91.7% at 5 years. These results compare favourably
well with the SRCT and DCRCG data [13,15]. If
one compares directly the 93-01 results with SRCT
and DCRCG, one should realize that in contrast to
the two randomized trials (hypofractionation/5/
5 Gy in one week followed by surgery after a short
interval), there are no patients with clinical stage I
disease in Trial 93-01.
The pattern of failure is dominated by the
appearance of distant metastases. In the SRCT and
the DCRCG the GD is rather homogeneous. In
these trials one cannot assess whether GD has any
influence on local control and distant metastases. In
the SRCT, patients are operated immediately after
the week-end break following the 5 times 5 Gy
applied in one week [15]. In the DCRCG the overall
treatment time (OTT), inclusive the gap, has to be
contained within 10 days starting at day 1 of the
radiotherapy although some variation in OTT has
been reported [13].
In Trial 93-01, the variability in GD allows an
evaluation of its potential impact on outcome.
However, we should be extremely cautious as we
cannot exclude that the present observation is just
due to hazard. We cannot retrospectively assess the
real reasons for this variability in GD. As a lot of
surgical centers and surgeons are participating in
Trial 93-01, we cannot eliminate selection biases and
other confounding factors. Moreover, Trial 93-01 is
a prospective non-randomized trial, not designed to
answer the question of the importance of GD. The
variability of the GD within Trial 93-01 is limited
essentially within 10 days. Biases cannot be ex-
cluded.
This variability of GD is difficult to explain a
posteriori . It might in part be due to the important
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Figure 1. Overall survival, cancer specific survival, disease free survival and local control are plotted as a function of GD. If GD/5 days see
dotted line.


































and possibly to surgeon’s misunderstanding of the
protocol guidelines. We cannot exclude that tumors
deemed to be marginally resectable, are submitted to
a longer GD to improve resection rates after a
potential downsizing. The published data on the
impact of short gaps on tumor downsizing and
downstaging are conflicting [2528]. Whether a
longer gap is important for increasing survival is still
an open question [29]. What seems to be clear,
however, is that one should try to obtain a clearance
(/lateral resection margin) as large as possible
[3032].
Nevertheless, the GD remains in the present
analysis a very powerful and independent prognostic
factor for OS, DFS and CSS. The observed differ-
ences are highly statistically significant and of
potential major clinical importance.
Local control rates are similar whether we
are dealing with a short (5/5 days) or a longer gap
(/5 days). However, one should remember that we
are dealing with only 16 local events. Therefore, in
the present analysis power is lacking to make any
conclusion on the impact of GD on local control.
GD seems primarily to influence the rate of distant
metastatic disease. We searched the literature in
order to find a possible explanation for the impor-
tance of GD on the appearance of distant metas-
tases. There are apparently no data available neither
clinical, nor experimental (in vivo animal models).
In an attempt to explain this phenomenon, we
intend to present four uncontrolled hypotheses
which should obviously be viewed cautiously and
submitted to experimental and clinical testing.
First of all, one can argue that quality of surgery may
influence the occurrence of distant metastases. As
shown by different groups, the quality of the surgery
does indeed directly determine the local risk. How-
ever, better quality surgery has apparently no effect on
the incidence of initial distant metastases [33].
Table I. Contingency analysis for patient- and tumor related
characteristics of potential prognostic importance (introduced as
categorical data) by gap duration. A significant association
between GD and any these characteristics a two-tailed Fisher’s
exact test yields a p-value 5/0.05. D.a.m. - distance to anal
margin. APR - abdominoperineal resection. T. volume - tumor







Female 33 53 0.59
Male 70 94
AgeB/64 48 69 1.00
Age]/64 55 78
CEA5/5 ng/ml 63 101 0.22
CEA/5 ng/ml 40 46
D.a.m5/5 cm 50 81 0.37
D.a.m./5 cm 53 66
cTB/4 80 126 0.13
cT4 23 21
APR 45 63 0.90
Other than APR 58 84
Different.B/3 79 91 0.02
Differentiation]/ 3 24 56
ClearanceB/3 mm 25 38 0.88
Clearance]/3 mm 78 109
pT/2 75 106 1.00
pT5/2 28 41
Downstaging 42 53 0.51
No downstaging 61 94
pN/ 47 71 0.70
pN0 56 76
No vascular invasion 78 115 0.65
Vascular invasion/ 25 32
Resection R0 88 118 0.32
Resection R 15 29
T. volume5/20cc * 72 102 1.00
T. volume/20cc 31 45
Cut-off value for volume correponds to the 75th percenrtile (*).
Table II. Univariate analysis of patient and treatment related
characteristics. The cut-off values are tabulated for each of the
parameters. If rated SS^ there is a statistically significant
difference between the strata with a p-value of 5/0.05 log-rank
test. NS*/difference not reaching a p-value B/0.05 (log-rank)
but reaching a p/0.03 with the Wilcoxon test. APR -
abdominoperineal resection; LAR - low anterior resection;
d.a.m. - distance to anal margin; clear - clearance i.e. lateral
resection margin; VI - vascular invasion; GD - gap duration in
days.
OS CSS DFS OS
Age 5/64 SS
CEA 5/5 ng/ml SS SS
d.a.m /5 cm SS
cT SS SS SS SS
GD 5/5 days SS SS SS
Surg. APR vs LAR SS
Clear B/3 mm SS SS SS SS
ypT T1 2 vs T3 4 SS SS SS
ypN / vs / SS SS SS
VI / vs / SS SS SS
R0 R0 vs R1 2 SS NS* SS SS
Table III. Univariate analysis for the parameter GD. The cut-off
value of 5/5 days is used to define the two strata. For the 2- and 5-
years results, in the upper line are tabulated the values for the
subgroup with a GD5/5 days, whereas the lower line represents
the patients with a GD/5 days. If the median is not reached, this
is labelled NR in the table. All survival figures are given in % with
the corresponding standard error.
p-value 2-years 5-years Median
OS 0.002 75%9/0.05 47%9/0.06 51 months
88%9/0.03 69%9/0.05 NR
CSS 0.0007 81%9/0.04 57%9/0.06 NR
94%9/0.02 82%9/0.04
DFS 0.0003 55%9/0.05 41%9/0.05 28 months
82%9/0.03 62%9/0.05 NR
LC NS 90%9/0.03 90%9/0.03 NR
96%9/0.02 93%9/0.03


































It is tempting to attribute the observed difference
in OS and DFS to a variation in the dynamics of
growth of distant metastatic deposits and changes in
angiogenesis and oxygen supply [34]. The question
remains open why there should be such a large
difference in outcome resulting from a rather small
difference in GD. It is well known that irradiation
does induce signalling cascades, and especially those
cascades linked to angiogenesis. Over-expression of
vascular endothelial growth factor (VEGF) has been
described after preoperative radiotherapy in rectal
cancer [35]. Overexpression of VEGF is also linked
to hypoxia induced Hypoxia inducible factor HIF-
1a. HIF-1a stimulates matrigel invasion by HCT-
116 human colon carcinoma cells in vitro [36].
Hypoxia in colorectal cancer promotes therefore an
invasive phenotype. As metallothionein (MT) are
considered by some authors as markers for residual
hypoxia, we tested whether in a subgroup of patients
issued from Trial 93-01 MT, predict outcome
[28,37]. In our data set we were not able to confirm
a relationship between the marker and patient out-
come [28]. However, residual hypoxia at the end of
HART as a stimulus for metastasis remains a
plausible hypothesis provided there is a difference
between strata in the level of hypoxia as a function of
time after the completion of the irradiation. In order
to highlight this difference, in vivo metabolic ima-
ging with PET technology or dynamic contrast
enhanced nuclear magnetic resonance technology
could be an option to demonstrate this hypothesis.
In the context of angiogenesis induced by irradia-
tion, it is interesting to note that a prolonged
treatment with angiostatin is able to reduce the
metastatic burden during radiation therapy [39].
The synergistic effect of a treatment with angiostatin
and irradiation is already observed after a brief
concomitant exposure in experimental conditions.
This is particularly important as there is evidence
that the treatment of the primary tumor by radiation
or surgery results in an increased secretion of pro-
angiogenic factors potentially stimulating the growth
of micrometastases. In advanced colorectal tumors,
the use of bevacizumab (Avastin†: Genentech,
South San Francisco, Ca) as a monoclonal antibody
directed against the vascular endothelial growth
factor receptor, has been validated in phase III trials
illustrating the importance of the pro-angiogenic
factors in disease progression [40]. Combinations
of bevacizumab and chemotherapy represent nowa-
days standard of care therapy for patients with
metastatic disease in the United States although
the mechanisms of its unique toxicity has not yet
been fully characterized [41,42]. It is however
unclear whether this approach is of any help in a
neo-adjuvant setting combined to irradiation [43].
Another interesting observation is a three- to four-
fold increase of active matrix metalloproteinases
(MMP) after radiotherapy [44,45]. These zinc-
containing enzymes are actively involved in the
degradation of the extracellular matrix, and hence
act as key-players in tumor invasion and spread.
Moreover, there is evidence that these enzymes play
a role in the angiogenesis process [46]. Kumar et al.
advanced the hypothesis that radiotherapy leads to
overexpression of type-IV collagenases in rectal
cancer (especially MMP-2 and MMP-9) [44].
They postulate that this might be at the origin of
the promotion of angiogenesis and in the re-estab-
lishment of invasion by remaining viable cancer cells
in an attempt to resurrect the growth potential of the
tumor [44,45]. A recent publication published by
Table IV. Multivariate analysis of patient and tumor related factors. The second column corresponds to the cut-off value. For each of the
parameters the p-value is listed (upper line) with the Risk Ratio (RR) and corresponding confidence limits (CL) (lower line). If the factor is
not kept in the final model, this factor is mentioned in the table as not significant (NS). GD - gap duration; VI - vascular invasion; a.m. -
anal margin. Patients in the defined subgroup have a better prognosis if the RRB/1.


















































































the same group shows that radiation results in
increased MMP expression in vitro for a limited
time period, resulting in an early increase in cell line
invasion on Matrigel [47].
To explain our clinical observation, we should
have a time dependency of the pro-angiogenic
response and metastatic prone factors after radio-
therapy. One might expect for example that the level
of circulating VEGF, known to be induced by
irradiation [48], encourages the growth of subclini-
cal disease. This level might be different immediately
after the end of the irradiation compared to the one
observed after a long time interval. If cells are shed
into circulation in optimal conditions, i.e. viable
after irradiation, they might well end up in a general
environment very suitable for metastasis. If the levels
of pro-angiogenic factors and metastatic prone
factors are falling as a function of time, surgery after
a delay of a couple of days might reduce the
metastatic potential of these tumor cells shed in the
circulation at surgery.
We are currently investigating on surgical speci-
mens whether there are significant differences in
hypoxia levels (HIF-1a), apoptosis levels (surviving)
[49], VEGF expression and type-IV collagenase
levels between strata defined by GD. As we are
analyzing the results on the surgical specimens only
and not on biopsies, the surgery may confound the
results as it can independently induce a number of
stress factors. But this is potentially true for both
groups whatever the GD. Another limitation of this
approach is that we do not have the pretreatment
values as we could not systematically recover the
diagnostic biopsies. However, one can argue that a
single biopsy is certainly not representative of the
mean status of the tumor for a particular growth
factor at the start of the treatment.
In conclusion, we did observe the impact of GD
on OS, CSS and DFS but not on local control.
Although we cannot exclude biases, we tentatively
advance the hypothesis that changes in the micro-
environment of the tumor induced by the irradiation
might be time dependent and hence influence
differentially the microscopic potential of surviving
cells at surgery. This should be tested in animal
models first before any extrapolation should be made
to clinical practice.
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